Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Assets (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Assets for 4 consecutive years, with $11.0 million as the latest value for Q4 2025.

  • Quarterly Assets rose 68.27% to $11.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.0 million through Dec 2025, up 68.27% year-over-year, with the annual reading at $11.0 million for FY2025, 68.27% up from the prior year.
  • Assets for Q4 2025 was $11.0 million at bioAffinity Technologies, down from $11.5 million in the prior quarter.
  • The five-year high for Assets was $14.1 million in Q3 2022, with the low at $4.8 million in Q2 2025.
  • Average Assets over 4 years is $8.9 million, with a median of $8.5 million recorded in 2023.
  • The sharpest move saw Assets tumbled 35.7% in 2024, then surged 76.23% in 2025.
  • Over 4 years, Assets stood at $12.2 million in 2022, then tumbled by 32.51% to $8.2 million in 2023, then fell by 20.77% to $6.5 million in 2024, then skyrocketed by 68.27% to $11.0 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $11.0 million, $11.5 million, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.